Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand.
AIDS. 1995 Sep;9(9):1079-83. Unique Identifier : AIDSLINE MED/96085725 Celentano DD; Beyrer C; Natpratan C; Eiumtrakul S; Sussman L; Renzullo PO; Khamboonruang C; Nelson KE; School of Hygiene and Public Health, Johns Hopkins University,; Baltimore, Maryland 21205, USA.
Abstract:
OBJECTIVES: To determine the anticipated participation in a prophylactic AIDS vaccine trial and to identify perceived benefits and barriers to enrollment of HIV-seronegative volunteers at risk of HIV infection in northern Thailand. DESIGN: A cross-sectional survey. METHODS: Subjects interviewed in a cross-sectional survey included female commercial sex workers (n = 215), men attending sexually transmitted disease clinics (n = 219), conscripts in the Royal Thai Army (n = 1453), and men discharged from the army (n = 293) who had returned to civilian life. We determined AIDS vaccine knowledge and attitudes, perceived vulnerability to HIV infection, barriers and incentives to participate in a future vaccine trial and agreement to participate in a randomized trial. RESULTS: Awareness of vaccines (88-97%) and AIDS vaccine development efforts (62-77%) were common and viewed to be a complement to behavior change (74-94%). Approximately 25% of subjects would definitely join a trial if asked, and an additional 38% would accept an AIDS vaccine if they were convinced it would be safe and effective. Important barriers to participation included concerns with discrimination (16-45%), short- (37-60%) and long-term (30-55%) vaccine side-effects, fear of disability and death (36-58%), and beliefs that partners would refuse to have sex (24-49%) after immunization. The principal inducement to join a trial was health insurance (62%). CONCLUSION: Potential HIV vaccine trial participants have several fears of joining a vaccine study at this time. Information derived from Phase I/II trials is needed to address these concerns if enrollment in efficacy trials is to be successful in the near future.
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*PREVENTION & CONTROL/TRANSMISSION Adult AIDS Vaccines/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/IMMUNOLOGY *Clinical Trials Cohort Studies Cross-Sectional Studies Female Human Knowledge, Attitudes, Practice Male Motivation *Patient Acceptance of Health Care Prostitution Risk Factors Support, Non-U.S. Gov't Support, U.S. Gov't, Non-P.H.S. Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE 960430
M9640863
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
